Pseudomonas aeruginosa Reduces VX-809 Stimulated F508del-CFTR Chloride Secretion by Airway Epithelial Cells
Bruce A Stanton1, Bonita Coutermarsh1, Roxanna Barnaby1
1Department of Microbiology and Immunology, The Geisel School of Medicine at Dartmouth, Hanover, New Hampshire, United States of America.
Background:
P. aeruginosa is an opportunistic pathogen that chronically infects the lungs of 85% of adult patients with Cystic Fibrosis (CF). Previously, we demonstrated that P. aeruginosa reduced wt-CFTR Cl secretion by airway epithelial cells. Recently, a new investigational drug VX-809 has been shown to increase F508del-CFTR Cl secretion in human bronchial epithelial (HBE) cells, and, in combination with VX-770, to increase FEV1 (forced expiratory volume in 1 second) by an average of 3-5% in CF patients homozygous for the F508del-CFTR mutation. We propose that P. aeruginosa infection of CF lungs reduces VX-809 + VX-770- stimulated F508del-CFTR Cl secretion, and thereby reduces the clinical efficacy of VX-809 + VX-770.
Methods And Results:
F508del-CFBE cells and primary cultures of CF-HBE cells (F508del/F508del) were exposed to VX-809 alone or a combination of VX-809 + VX-770 for 48 hours and the effect of P. aeruginosa on F508del-CFTR Cl secretion was measured in Ussing chambers. The effect of VX-809 on F508del-CFTR abundance was measured by cell surface biotinylation and western blot analysis. PAO1, PA14, PAK and 6 clinical isolates of P. aeruginosa (3 mucoid and 3 non-mucoid) significantly reduced drug stimulated F508del-CFTR Cl secretion, and plasma membrane F508del-CFTR.
Conclusion:
The observation that P. aeruginosa reduces VX-809 and VX-809 + VX-770 stimulated F508del CFTR Cl secretion may explain, in part, why VX-809 + VX-770 has modest efficacy in clinical trials.
Insights
Pseudomonas aeruginosa infection reduces the effectiveness of CFTR modulator drugs like VX-809 and VX-770 in cystic fibrosis (CF) patients. This bacterial lung infection impairs drug-stimulated chloride secretion, potentially explaining modest clinical trial results.
Area of Science:
- Pulmonary Medicine
- Microbiology
- Genetics
Background:
- Cystic Fibrosis (CF) affects 85% of adult patients with chronic lung infections by *Pseudomonas aeruginosa*.
- P. aeruginosa infection reduces wild-type CFTR chloride secretion in airway epithelial cells.
- Investigational drugs VX-809 and VX-770 improve F508del-CFTR chloride secretion and FEV1 in CF patients.
Purpose of the Study:
- To investigate the impact of *P. aeruginosa* infection on VX-809 and VX-770 stimulated F508del-CFTR chloride secretion.
- To determine if *P. aeruginosa* reduces the clinical efficacy of these CFTR modulator drugs.
Main Methods:
- Exposure of F508del-CFBE and primary CF-HBE cells to VX-809 alone or in combination with VX-770.
- Measurement of F508del-CFTR chloride secretion using Ussing chambers.
- Assessment of F508del-CFTR abundance via cell surface biotinylation and western blot analysis.
Main Results:
- *P. aeruginosa* (including clinical isolates) significantly reduced VX-809 and VX-809 + VX-770 stimulated F508del-CFTR chloride secretion.
- Bacterial infection also decreased plasma membrane F508del-CFTR levels.
- Multiple strains of *P. aeruginosa* demonstrated this inhibitory effect.
Conclusions:
- *P. aeruginosa* infection diminishes the chloride secretion stimulated by VX-809 and VX-809 + VX-770 in F508del-CFTR cells.
- This interaction may partially explain the modest clinical efficacy observed with VX-809 + VX-770 in CF patients.
- Targeting *P. aeruginosa* infection could enhance the effectiveness of CFTR modulator therapies.
More Related Videos
Related Concept Videos
Gene Regulation in Microbial Communities: Quorum Sensing
Cystic Fibrosis: Pathogenesis
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
Cystic Fibrosis: Management
Sinus disease and chronic...


